Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Vaccines for pandemics.

Literature DB >> 24213761

Vaccines for pandemics.

Charles Schmidt.

Abstract

Mesh：

Substances：
Influenza Vaccines

Year: 2013 PMID： 24213761 DOI： 10.1038/nbt.2733

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

6 in total

1. BARDA funds vaccine makers aiming to phase out eggs.

Authors: Stephen Strauss
Journal: Nat Biotechnol Date: 2010-12 Impact factor: 54.908

2. Synthetic generation of influenza vaccine viruses for rapid response to pandemics.

Authors: Philip R Dormitzer; Pirada Suphaphiphat; Daniel G Gibson; David E Wentworth; Timothy B Stockwell; Mikkel A Algire; Nina Alperovich; Mario Barro; David M Brown; Stewart Craig; Brian M Dattilo; Evgeniya A Denisova; Ivna De Souza; Markus Eickmann; Vivien G Dugan; Annette Ferrari; Raul C Gomila; Liqun Han; Casey Judge; Sarthak Mane; Mikhail Matrosovich; Chuck Merryman; Giuseppe Palladino; Gene A Palmer; Terika Spencer; Thomas Strecker; Heidi Trusheim; Jennifer Uhlendorff; Yingxia Wen; Anthony C Yee; Jayshree Zaveri; Bin Zhou; Stephan Becker; Armen Donabedian; Peter W Mason; John I Glass; Rino Rappuoli; J Craig Venter
Journal: Sci Transl Med Date: 2013-05-15 Impact factor: 17.956

3. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.

Authors: I Margine; F Krammer; R Hai; N S Heaton; G S Tan; S A Andrews; J A Runstadler; P C Wilson; R A Albrecht; A García-Sastre; P Palese
Journal: J Virol Date: 2013-07-31 Impact factor: 5.103

4. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

Authors: Benjamin Petsch; Margit Schnee; Annette B Vogel; Elke Lange; Bernd Hoffmann; Daniel Voss; Thomas Schlake; Andreas Thess; Karl-Josef Kallen; Lothar Stitz; Thomas Kramps
Journal: Nat Biotechnol Date: 2012-11-25 Impact factor: 54.908

5. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.

Authors: Surender Khurana; Crystal L Loving; Jody Manischewitz; Lisa R King; Phillip C Gauger; Jamie Henningson; Amy L Vincent; Hana Golding
Journal: Sci Transl Med Date: 2013-08-28 Impact factor: 17.956

6. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies.

Authors: Masaru Kanekiyo; Chih-Jen Wei; Hadi M Yassine; Patrick M McTamney; Jeffrey C Boyington; James R R Whittle; Srinivas S Rao; Wing-Pui Kong; Lingshu Wang; Gary J Nabel
Journal: Nature Date: 2013-05-22 Impact factor: 49.962

6 in total

4 in total

Vaccines for pandemics.

1. BARDA funds vaccine makers aiming to phase out eggs.

2. Synthetic generation of influenza vaccine viruses for rapid response to pandemics.

3. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses.

4. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection.

5. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease.

6. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies.

1. Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

2. Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza.

3. Hybrid biosynthetic gene therapy vector development and dual engineering capacity.

4. Design Variation of a Dual-Antigen Liposomal Vaccine Carrier System.